Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to higher doses of its oral drug was "limited" in its latest trial results. Morning Brief's Seana Smith and Brad Smith report on what this story means for the company.

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.

The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that delivered weight loss success by taking a daily pill. Novo Nordisk released data Wednesday showing that patients taking its new medication,

Weight loss injections are essentially the opposite of pills in terms of pros and cons. They’re generally more effective and there are fewer restrictions around the timing of the dose than pills. They’re typically only taken once per week, which may be an easier schedule to stick to, especially for people who don’t take many medications regularly.

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster weight loss than Wegovy in early clinical trials, according to data presented Wednesday at the European Association for the Study of Diabetes.

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing.

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.